Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) unit sales to US wholesalers and institutional vial orders for its fiscal fourth quarter ended 30 September 2026.
A total of 792 units were purchased by US wholesalers in the three-month period, compared to 360 units in the three months to 30 June 2026, an increase of 120%.
Additionally, 950 LYMPHIR vials were ordered by prescribing centres from wholesalers, compared to 926 in the prior quarter.
To date, 54 institutions have ordered LYMPHIR, compared to 44 as of 14 August 2026, as last reported.
LYMPHIR is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. LYMPHIR was approved by the FDA and subsequently launched in the United States in December 2025.
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
Solventum's combined use of Restrata Matrix and Solventum VAC Therapy receives FDA 510(k) clearance
Viatris' RYZUMVI receives US FDA Approval to treat presbyopia
Omeros receives negative EU opinion on narsoplimab after re-examination
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
LTR Pharma launches Roxus nasal spray for ED in the US
Genezen agrees manufacturing collaboration with Galibra Neuroscience
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
FDA approves Vantis Vascular's 6F CrossFAST model
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201